Ranchi News Desk

Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight

 Breaking News
  • No posts were found

Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight

December 07
05:16 2022
Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report

  • DelveInsight’s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Viruses Cancer treatment. 
  • Leading Oncolytic Virus Cancer Therapy companies such as Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc., Imvaq Therapeutics, Seneca Therapeutics, AmunBio, Orgenesis, Protheragen, Astellas Pharma, MedImmune LLC, Istari Oncology, Inc., Treovir LLC, and others are evaluating novel Oncolytic Virus Cancer Therapies to improve the treatment landscape.
  • Key Oncolytic Virus Cancer Therapies in the pipeline in various stages of development include LOAd703, V937, OH2, CG0070, OBP-301, Vusolimogene oderparepvec, TG6002, Invir.IOTM based armed oncolytic immunotherapies, STI-1386, ORCA-010, TILT-123, CRX 100, Pelareorep, ONCR-177, ONCR-GBM, ONCR-021, ONCR-788, DNX-2401, DNX-2440, vMYX-hIL-12/Dec, Voyager-V1, MV-NIS, VCN 01, VCN 02, VCN 03, VCN 11, VSV-GP, CF33, RIVAL 01, MVR-T3011, Pexa-Vec, CAN-2409, CAN-3110, NOUS 209, NOUS PEV,  TVP 211, ELC-100, ELC-201, Valo D102, TT 16, NG 641, NG 350A, NG 348, NG 347, VET2 L2, VET3 NK, VET1 S3, ONCOS-102, MB-108, HF10, VAX014, NNV-1, NNV 2, SNV 1, AAA1, Olvi-Vec, BT-001, SND005, AdAPT-001, SVV-001, Celyvir, RV-scFv-PDL1, OV FV 01,  ASP9801, MEM 288, MEDI5395, PVSRIPO, G207, and others.
  • The Oncolytic Virus Cancer Therapies Companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches to treat/improve Oncolytic Virus Cancer Therapy.

 

Recent Developmental Activities in the Oncolytic Virus Cancer Therapy Pipeline

  • In January 2022, Lokon Pharma AB, announced a collaboration with Affibody AB (“Affibody”) to combine oncolytic viruses with Affibody® molecules.
  • In December 2021, Transgene announced that AstraZeneca had exercised its first license option for an Invir.IO™ oncolytic virus (OV) developed from their on-going OV collaboration. The exercise of this option for an OV, integrating an undisclosed transgene, resulted in Transgene receiving an $8 million payment from AstraZeneca. 
  • In December 2021, Sorrento Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumors.
  • In April 2022, OncoMyx Therapeutics announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2022 (April 8-13). The data presented at AACR 2022 demonstrate that OncoMyx’s myxoma virus multi-armed with IL-12 and decorin infects and kills human multiple myeloma cells in vitro and demonstrates dose responsive efficacy after intravenous (IV) administration in a mouse model of multiple myeloma.
  • In March 2022, Synthetic Biologics, Inc. announced the peer-reviewed publication of a Phase 1, multicenter, open-label, dose-escalation study investigating the therapeutic potential of intravenous VCN-01 oncolytic adenovirus with or without standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) in patients with advanced solid tumors. The data, published in the Journal for ImmunoTherapy of Cancer, suggests that treatment with VCN-01 is feasible and has an acceptable safety profile, with encouraging biological and clinical activity.These findings provide valuable dose-finding context and inform the clinical development strategy forVCN-01.
  • In March 2022, ImmVira’s breakthrough intravenous oncolytic virus product MVR-T3011 IV completed its first dosing in Phase I clinical trial in China.

 

Request a sample and discover the recent advances in the Oncolytic Virus Cancer Therapy treatment @ Oncolytic Virus Cancer Therapy Pipeline Outlook Report

 

Oncolytic Virus Cancer Therapy Overview

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

 

Oncolytic Virus Cancer Therapy Emerging Drugs Profile

  • Olvi-Vec: Genelux Corporation
  • CAN-2409: Candel Therapeutics
  • CG0070: CG Oncology
  • Pelareorep: Oncolytics Biotech
  • ParvOryx: Oryx GmbH
  • SND005: Jiangsu Sinorda Biomedicine
  • VCN-01: VCN Biosciences

 

Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.

 

Find out more about viruses to kill cancer cells @ Oncolytic Virus Cancer Therapy Ongoing Clinical Trials Analysis

 

Oncolytic Virus Cancer Therapy Segmentation

The Oncolytic Virus Cancer Therapy Pipeline report proffers an integral view of the Oncolytic Virus Cancer Therapy emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Scope of the Oncolytic Virus Cancer Therapy Pipeline

  • Coverage: Global 
  • Oncolytic Virus Cancer Therapy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Oncolytic Virus Cancer Therapy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Oncolytic Virus Cancer Therapy Therapeutics Assessment By Route of Administration: Intravenous, Intradermal, Intramuscular, Intravesicular, Intratumoral, Oral, Subcutaneous, Topical, 
  • Oncolytic Virus Cancer Therapy Therapeutics Assessment By Molecule Type: Vaccines, Small molecule, Polymers, Peptides, Monoclonal antibodies, Immunotherapy
  • Oncolytic Virus Cancer Therapy Therapeutics Assessment By Mechanism of Action: Cell death stimulants, Granulocyte macrophage colony stimulating factor agonists, Granulocyte-macrophage colony-stimulating factor expression stimulants, Immunologic cytotoxicity, Antibody-dependent cell cytotoxicity, Interleukin-12 expression stimulants, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Immunostimulants
  • Key Oncolytic Virus Cancer Therapy Companies: Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Amgen, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc., Imvaq Therapeutics, Seneca Therapeutics, AmunBio, Orgenesis, Protheragen, Astellas Pharma, MedImmune LLC, Istari Oncology, Inc., Treovir LLC, and others
  • Key Oncolytic Virus Cancer Therapy Pipeline Therapies: LOAd703, V937, OH2, CG0070, Talimogene laherparepvec, OBP-301, Vusolimogene oderparepvec, TG6002, Invir.IOTM based armed oncolytic immunotherapies, STI-1386, ORCA-010, TILT-123, CRX 100, Pelareorep, ONCR-177, ONCR-GBM, ONCR-021, ONCR-788, DNX-2401, DNX-2440, vMYX-hIL-12/Dec, Voyager-V1, MV-NIS, VCN 01, VCN 02, VCN 03, VCN 11, VSV-GP, CF33, RIVAL 01, MVR-T3011, Pexa-Vec, CAN-2409, CAN-3110, NOUS 209, NOUS PEV,  TVP 211, ELC-100, ELC-201, Valo D102, TT 16, NG 641, NG 350A, NG 348, NG 347, VET2 L2, VET3 NK, VET1 S3, ONCOS-102, MB-108, HF10, VAX014, NNV-1, NNV 2, SNV 1, AAA1, Olvi-Vec, BT-001, SND005, AdAPT-001, SVV-001, Celyvir, RV-scFv-PDL1, OV FV 01,  ASP9801, MEM 288, MEDI5395, PVSRIPO, G207, and others.

 

Table of Content

  1. Introduction
  2. Oncolytic Virus Cancer Therapy Executive Summary
  3. Oncolytic Virus Cancer Therapy: Overview
  4. Oncolytic Virus Cancer Therapy Pipeline Therapeutics
  5. Oncolytic Virus Cancer Therapy Therapeutic Assessment
  6. Oncolytic Virus Cancer Therapy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Olvi-Vec: Genelux Corporation
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SND005: Jiangsu Sinorda Biomedicine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AloCelyvir: Orgenesis
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. VCN-01: VCN Biosciences
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. SynOV 1.3: Beijing Syngentech
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Oncolytic Virus Cancer Therapy Key Companies
  24. Oncolytic Virus Cancer Therapy Key Products
  25. Oncolytic Virus Cancer Therapy- Unmet Needs
  26. Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
  27. Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
  28. Oncolytic Virus Cancer Therapy Analyst Views
  29. Oncolytic Virus Cancer Therapy Key Companies
  30. Appendix

 

Key Questions

Current Scenario and Emerging Therapies: 

  • How many companies are developing Oncolytic Virus Cancer Therapy pipeline drugs?
  • How many Oncolytic Virus Cancer Therapy pipeline drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy pipeline?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Dive deep into rich insights for Oncolytic virus therapy, visit @ Oncolytic virus therapy Companies & Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles